Arrhythmias & electrophysiologyCohort study

Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study

Heart RhythmPublished

  • global, prospective, observational study
  • postapproval registry

Authors' conclusion

In routine practice, iATP was highly effective and safe across all VT rates. Although exploratory, iATP had overall superior termination rates and a lower chance of acceleration resulting in shock than standard ATP.

Study context

Population
Patients with an Intrinsic ATP (iATP)-enabled implantable cardioverter-defibrillator or cardiac resynchronization therapy-defibrillator deviceenrolled patients, followed for a total of 3200 patient-years, yielding 2575 iATP-treated monomorphic ventricular tachycardia (MVT) episodes
Participants
1,875 patients
Exposure
iATP effectiveness in terminating MVT episodes in the fast ventricular tachycardia (VT) zone against >60% objective; post hoc comparison of iATP with standard antitachycardia pacing (ATP) from a retrospective cohort
  • iATPn = 1,875
Outcome
Termination of MVT episodes in the fast VT zone (objective >60%)

Main finding

As reported in the abstract

iATP

89.7%

Generalized estimating equations (GEE)-estimated success rate · 95% CI 83.6–93.7

Observational data: associations, not effects.

Further findings

Outcomeadjusted odds ratio (95% CI)P value
VT termination, iATP vs standard ATP (post hoc) · post hoc, exploratory1.87 (1.32–2.66)P = 0.0005

Safety

OutcomeiATPstandard ATPadjusted odds ratio (95% CI)P value
iATP-associated MVT acceleration resulting in shock · post hoc, exploratoryGEE-estimated rate 2.3%Not reported in the abstract0.43 (0.25–0.74)P = 0.0026

Original publication

Real-world performance of intrinsic antitachycardia pacing: Primary results from a global prospective postapproval registry study. Heart Rhythm. Published 5 January 2026. doi:10.1016/j.hrthm.2025.12.039

Summarised from the published abstract; every number is checked against it